[1] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl),2022,135(5): 584-590. DOI: 10.1097/CM9.0000000000002108.
[2] 魏文海, 李兴芳, 赵琼, 等. PI3K/Akt/mTOR信号通路抗非小细胞肺癌的机制及中药干预研究进展[J]. 中国实验方剂学杂志, 2023, 29(23): 218-226. DOI: 10.13422/j.cnki.syfjx.20230221.
[3] Miller BC, Sen DR, Abosy Al R, et al. Subsets of Exhausted CD8+ T Cells Differentially Mediate Tumor Control and Respond to Checkpoint Blockade[J]. Nat Immunol, 2019, 20:326-36. DOI: 10.1038/s41590-019-0312-6.
[4] 闵翼, 张曦尧, 向东阳, 等. 芡茎多糖通过诱导CD4+ T、CD8+ T和NK细胞的浸润促进小鼠肺癌LLC细胞凋亡[J]. 南京中医药大学学报, 2023, 39(7):637-644. DOI: 10.14148/j.issn.1672-0482.2023.0637.
[5] 兰煜, 范国栋, 王婷, 等. 芪玉三龙汤调节小鼠腹腔巨噬细胞M2/M1型极化及其对CD4+、CD8+T细胞的影响[J]. 安徽中医药大学学报, 2023, 42(4):88-92. DOI: 10.3969/j.issn.2095-7246.2023.04.019.
[6] 莫娟梅, 张顺荣, 梁潇, 等. 壮药扶正复方辅助治疗晚期表皮生长因子受体敏感型突变非小细胞肺癌临床研究[J]. 国际中医中药杂志, 2022, 44(10):1102-1106. DOI:10.3760/cma.j.cn115398-20211222-00233.
[7] 陈康, 金晨, 程玉瑶, 等. 基于网络药理学和分子对接探讨鸡血藤治疗肺癌的分子作用机制[J]. 中国中药杂志, 2021, 46(4):837-844. DOI: 10.19540/j.cnki.cjcmm.20201118.401.
[8] Zheng J, Wu M, Wang H, et al. Network pharmacology to unveil the biological basis of health-strengthening herbal Medicine in cancer treatment[J]. Cancers (Basel), 2018, 10(11):461. DOI: 10.3390/cancers 10110461.
[9] 莫娟梅, 甘芷川, 张顺荣, 等. 扶正方对Lewis肺癌小鼠免疫功能、PI3K/AKT信号通路和外周血IL-2、IL-6、INF-γ的影响[J]. 现代生物医学进展, 2021, 21(23):4422-4426. DOI: 10.13241/j.cnki.pmb. 2021. 23.005.
[10] 张志超, 刘江红, 潘远安. 五指毛桃与黄芪提取物对免疫抑制小鼠细胞免疫的影响[J].中国民族民间医药, 2017, 26(5):58-59. DOI: 10.3969/j.issn.1007-8517.2017.5.zgmzmjyyzz201705018.
[11]张嫦丽, 张可锋, 许有瑞, 等. 黄花倒水莲的化学成分与药理活性研究进展[J]. 中国药房, 2017, 28(19):2724-2728. DOI: 10.6039/j.issn.1001-0408.2017.19.35.
[12]毛跃程, 邢代君, 刘心宁, 等. 汉黄芩素对气虚模型LLC种植瘤小鼠的抗肿瘤作用及淋巴细胞亚群的影响[J]. 中医药导报, 2023, 29(6):1-9. DOI: 10.13862/j.cn43-1446/r.2023.06.001.
[13]Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting[J]. Nat Rev Cancer, 2015,15:7-24. DOI: 10.1038/nrc3860.
[14]Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations[J]. Nat Rev Cancer. 2009, 9:550-562. DOI: 10.1038/nrc2664.
|